From SPPAN (State Pain Policy Advocacy Network)

SPPAN and the American Academy of Pain Management are paying close attention to these policy issues because we believe that Zohydro ER is an important new option for some people with pain who require opioid analgesics as part of their pain care plan. Although many policymakers have asserted otherwise, in our view, Zohydro ER is no different from any other non-ADF extended-release opioid on the market, and, therefore, we believe it ought to be regulated in the same way as those other products. To us, that is a logical approach to this new medication, one that responds to concerns about it with a rational, evidence-based policy solution.

In this update, you will find a few recent headlines that pertain to Alabama, Massachusetts, and ADF.

View the Full SPPAN Update